about
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerGenotoxic anti-cancer agents and their relationship to DNA damage, mitosis, and checkpoint adaptation in proliferating cancer cellsStructure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapiesCell cycle checkpoint in cancer: a therapeutically targetable double-edged swordA phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.Identification of ATR-Chk1 pathway inhibitors that selectively target p53-deficient cells without directly suppressing ATR catalytic activity.Comparative analysis of radiosensitizers for K-RAS mutant rectal cancersSensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments.Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma.mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibitionRapamycin-induced autophagy sensitizes A549 cells to radiation associated with DNA damage repair inhibition.Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase.Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.Human cells enter mitosis with damaged DNA after treatment with pharmacological concentrations of genotoxic agents.Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.Repairing of N-mustard derivative BO-1055 induced DNA damage requires NER, HR, and MGMT-dependent DNA repair mechanismsEpi-reevesioside F inhibits Na+/K+-ATPase, causing cytosolic acidification, Bak activation and apoptosis in glioblastomaRad51 in regulating the radiosensitivity of non-small cell lung cancer with different epidermal growth factor receptor mutation status.Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design.The Saccharomyces cerevisiae F-box protein Dia2 is a mediator of S-phase checkpoint recovery from DNA damage.Hypoxia attenuates Hsp90 inhibitor 17-DMAG-induced cyclin B1 accumulation in hepatocellular carcinoma cells.A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.Compensation, crosstalk and sequestering: the currency of checkpoints in cancerATF2 knockdown reinforces oxidative stress-induced apoptosis in TE7 cancer cells.Effects of salidroside on glioma formation and growth inhibition together with improvement of tumor microenvironmentHyperthermia enhances 17-DMAG efficacy in hepatocellular carcinoma cells with aggravated DNA damage and impaired G2/M transitionIs activation of the intra-S checkpoint in human fibroblasts an important factor in protection against UV-induced mutagenesis?Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancerRadiation-induced signaling pathways that promote cancer cell survival (review).Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer.Design, Synthesis and Evaluation of Naphthalimide Derivatives as Potential Anticancer Agents for Hepatocellular Carcinoma.Carbazole Aminoalcohols Induce Antiproliferation and Apoptosis of Human Tumor Cells by Inhibiting Topoisomerase I.Targeting the ATR-CHK1 Axis in Cancer TherapyZGDHu-1 induces G₂/M phase arrest and apoptosis in Kasumi-1 cells.Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells.
P2860
Q26783551-CD2C3103-1794-45B3-91FB-2357FCB97931Q26851196-9BE87E17-F76D-4C65-900D-5A70F8068A8BQ26864870-E5FF9C1A-34DE-47F8-9511-E4AFAE4FB399Q28078268-9180FBCE-6D90-4C95-B6BC-B02D71D75A4AQ30422919-B40E46B4-9CA9-40DC-A80B-20BF6F8399C1Q34603025-ED871B73-7A4D-42DB-B101-611289AB0789Q34715440-B815AD45-6457-43A7-B475-702C9D6776BDQ35070685-1FCA262C-98F5-476A-971E-8F8629009770Q35073758-F6AD9309-F551-4C9F-B37E-3050EAE503D9Q35201518-58BC69F6-92C0-4757-B2C7-7AEE92DC0C90Q35657004-88F9E539-3725-4AB7-A1C9-815CF7F12E08Q35809470-EC564D96-DAD1-4C87-82B3-004549C369ABQ36069410-806B2918-DCF3-4491-B5CA-4C423E86B211Q36187661-7996224C-C10C-4C73-9141-A20109CBF1FAQ36189324-165D1027-4136-457E-9A23-64B69D539F4EQ36196359-801EF762-6604-4689-9762-E029F5B05FFAQ36214686-20954EB0-450D-4F0C-A642-28CB5BF24CFCQ36413288-F996F1B7-09ED-4B11-9635-F7218AE22739Q36414371-CCED5483-EFCD-4640-87E5-1A99A048BE68Q36477745-CFD6F79C-5A90-4C43-95B8-7C402CC67DF1Q36544857-AC5CB4F8-CA3B-4560-B9DB-2613B9E91977Q36546469-77082E30-84B0-4CE6-BBC1-13EFB1C0642EQ36596489-0D4E3302-BC4A-4E37-AE5E-41AEDA95EC80Q36674083-4FAF5720-270D-4821-9573-F1E156300579Q36738836-648D6A99-5DCB-4C69-AC51-27697AD8AA27Q36906221-FBB49BF2-8E82-4EFC-9E17-FD83AEB57B94Q37191024-5B2E7C20-1F16-474B-B5E9-7856661F73A0Q37309461-196AFBCC-C643-4012-8AF3-3913DCFE605EQ37464190-2D736BAD-364C-454F-B708-4CE036EC10BBQ37530284-195EC867-8CA1-4A6E-8016-BF265E23D440Q37635766-7C69B0BB-E7F8-4350-AFC4-6F7C6BB7A41FQ37743501-02A2F850-6A3F-4DE2-B243-F64E9AD3FE86Q38244964-8BC5994E-D369-4011-BF13-361278F91D9EQ38523589-D8400705-2085-4146-AFC3-60D2735282EBQ38714663-2698FD09-4B42-4CAB-99C3-DE3EACF5F99BQ38729365-F992C393-5C9B-4C26-BAA8-796CC52DB2A5Q38817102-133B7CB8-B07F-42BC-8E74-B280C6ABD898Q38921796-9733B5AE-E163-48AD-82F6-A88BCEEF1759Q38932758-F19AE5AD-6CA0-43FC-B0C5-DCD52473C8ECQ39064254-D93E255A-C535-490D-BD0C-39C373E3216C
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting the S and G2 checkpoint to treat cancer.
@en
Targeting the S and G2 checkpoint to treat cancer.
@nl
type
label
Targeting the S and G2 checkpoint to treat cancer.
@en
Targeting the S and G2 checkpoint to treat cancer.
@nl
prefLabel
Targeting the S and G2 checkpoint to treat cancer.
@en
Targeting the S and G2 checkpoint to treat cancer.
@nl
P2093
P1433
P1476
Targeting the S and G2 checkpoint to treat cancer
@en
P2093
Fiona K Middleton
Peter A Stephens
P304
P356
10.1016/J.DRUDIS.2011.12.009
P577
2011-12-15T00:00:00Z